Menu Back toV8-S6

14th DIA Japan Annual Meeting 2017

[V8-S6] For Providing the Most Appropriate Medicine - The Current State of Use and Development of Companion Diagnostics (Mainly on Next Generation Sequencers)

    Session Chair(s)
      Kazuto  Nishio, MD

      Kazuto Nishio, MD

      • Professor
      • Kindai University Faculty of Medicine, Japan
    The existence of companion diagnostics is important for delivering medicine suitable for each patient. Genomic analysis is performed using next generation sequencer in cancer genome medical treatment, and genomic mutation for each patient and cell is revealed. In this session, present current status of “Precision Medicine” using Next Generation Sequencer, Issues in using next-generation sequencers, and issues of companion diagnostic drug development from the standpoint of each industry, government and academia. And also discuss the solution on panel-discussion.
      Reiko  Yanagihara, PhD

      Regulatory Perspectives on NGS-based CDx

      Reiko Yanagihara, PhD

      • Deputy Review Director, Office of In Vitro Diagnostics
      • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
      Takashi  Kohno, PhD

      NGS-Based Clinical Sequencing System for Precision Cancer Medicine in Japan

      Takashi Kohno, PhD

      • Division of Genome Biology
      • National Cancer Center Research Institute, Japan
      Miwa  Nishida

      Issue on the Development of CoDxs from Diagnostics Company’s Points of View

      Miwa Nishida

      • Sr. Manager, Clinical Operations, Medical, Quality & Regulatory
      • Roche Diagnostics K.K., Japan
      Michio  Tanaka

      Development of NGS- based CDx from a Pharmaceutical Company’s Viewpoint

      Michio Tanaka

      • Senior Director, Science Affairs Division, R&D
      • AstraZeneca K.K., Japan

Contact us

Please contact the DIA Japan office in Tokyo for further information.

Tel: +81-3-6214-0574
Fax: +81-3-3278-1313